Last $43.38 USD
Change Today +0.48 / 1.12%
Volume 4.8M
ABT On Other Exchanges
Symbol
Exchange
New York
Mexico
SIX Swiss Ex
Sao Paulo
Frankfurt
As of 8:04 PM 09/17/14 All times are local (Market data is delayed by at least 15 minutes).

abbott laboratories (ABT) Snapshot

Open
$42.94
Previous Close
$42.90
Day High
$43.57
Day Low
$42.76
52 Week High
09/17/14 - $43.57
52 Week Low
10/9/13 - $32.75
Market Cap
65.2B
Average Volume 10 Days
4.0M
EPS TTM
$1.70
Shares Outstanding
1.5B
EX-Date
10/10/14
P/E TM
25.5x
Dividend
$0.88
Dividend Yield
1.84%
Current Stock Chart for ABBOTT LABORATORIES (ABT)

abbott laboratories (ABT) Details

Abbott Laboratories manufactures and sells health care products worldwide. Its Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome, intrahepatic cholestasis or depressive symptoms, gynecological disorders, dyslipidemia, hypertension, hypothyroidism, pain, fever, and inflammation; and regulates physiological rhythm of the colon, as well as provides hormone replacement therapy and anti-infective and influenza vaccines. The company’s Diagnostic Products segment provides diagnostic systems and tests, such as immunoassay and clinical chemistry systems; assays for screening and diagnosis for drugs of abuse, cancer, therapeutic drug monitoring, fertility, and physiological and infectious diseases; hematology systems and reagents; genomic-based tests; informatics and automation solutions; and diagnostic systems and tests for blood analysis, as well as instruments that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detects and measures infectious agents. Its Nutritional Products segment offers pediatric and adult nutritional products, such as various forms of prepared infant and follow-on formula. The company’s Vascular Products segment provides coronary, endovascular, vessel closure, and structural heart devices for the treatment of vascular diseases. Abbott Laboratories also offers blood glucose and glucose monitoring systems, test strips, and data management software and accessories for people with diabetes; and medical devices for the eye, such as cataract surgery, LASIK surgery, and contact lens care and dry eye products. The company primarily serves retailers, wholesalers, hospitals, health care facilities, laboratories, physicians’ offices, and government agencies. It has strategic alliance with Fonterra Co-operative Group Ltd. The company was founded in 1888 and is headquartered in Abbott Park, Illinois.

69,000 Employees
Last Reported Date: 02/21/14
Founded in 1888

abbott laboratories (ABT) Top Compensated Officers

Chairman, Chief Executive Officer and Chairma...
Total Annual Compensation: $1.9M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $969.7K
Executive Vice President, General Counsel and...
Total Annual Compensation: $650.0K
Executive Vice President of Diagnostic Produc...
Total Annual Compensation: $614.6K
Executive Vice President of Corporate Develop...
Total Annual Compensation: $629.5K
Compensation as of Fiscal Year 2013.

abbott laboratories (ABT) Key Developments

Abbott Initiates ABSORB IV Trial to Evaluate Quality of Life and Cost Savings of Dissolving Heart Device

Abbott announced the start of the ABSORB IV clinical trial, which will test whether its Absorb Bioresorbable Vascular Scaffold (BVS) is more cost-effective and offers a higher quality of life than a best-in-class, permanent, metallic drug eluting stent. Absorb is the world's first drug eluting BVS and functions like a metallic stent by opening up blocked blood vessels in the heart and restoring blood flow. However, unlike a metallic stent, Absorb completely dissolves over time after doing its job. ABSORB IV is designed to enroll approximately 3,000 people with coronary artery disease, mostly in the United States. ABSORB IV is the first randomized heart stent trial to prospectively measure angina as a primary endpoint at one year. Angina is commonly described as chest pain and is caused by reduced flow of oxygen-rich blood to the heart. Measuring angina is significant because of its impact on quality of life and healthcare costs. Overall, people who have angina following a percutaneous coronary intervention (PCI) use more healthcare resources than those without angina. Studies have shown that while PCI with metallic stents is highly effective, by reducing angina for 75% of treated patients, about 25% of people treated still experience angina over the course of the year following PCI. In addition, people with frequent angina typically have a lower quality of life because they are less likely to lead active lifestyles than those without angina. Randomized data recently presented from the ABSORB II clinical trial, conducted primarily in Europe, showed that people treated with Absorb experienced significantly less angina compared to those who received a permanent metallic stent. The ABSORB IV trial is designed to confirm these novel findings that treatment with the Absorb device can help provide people with heart disease a higher quality of life after a heart stent procedure. The other primary endpoint of ABSORB IV assesses long-term clinical safety and performance based on the change in target lesion failure (TLF) from one to five years. TLF is a traditional endpoint in heart stent trials used to measure the safety and effectiveness of a device. Data from the ABSORB II clinical trial showed a similar rate of TLF between Absorb and XIENCE at one year. ABSORB IV is designed to demonstrate that this performance is consistent out to five years in people treated in the U.S.

Advanced Biological Laboratories Enters Promotional Agreement with Abbott for Innovative Software Suite in HIV Genotyping

Advanced Biological Laboratories (ABL) S.A. announced that it has granted Abbott non-exclusive rights to market ABL's software suite for HIV genotyping data analysis. Abbott will utilize its expertise in infectious disease diagnostics to offer ABL products for HIV genotyping, and facilitate access to the newest and up-to-date analysis of HIV genotyping to its customers in the United States.

Abbott Announces Clinical Results from Absorb II

Abbott announced positive one-year clinical results from ABSORB II, the world's first prospective, randomized, controlled trial comparing the safety and effectiveness of the dissolving Absorb heart device to Abbott's metallic XIENCE family of DES. At one year, overall clinical outcomes for Absorb were comparable to XIENCE, and people treated with Absorb experienced a significantly lower rate of angina (chest pain), a novel finding given the impact of angina on people's quality of life and its cost burden on healthcare systems. Absorb is a first-of-its-kind device that functions like a metallic stent by opening a blocked artery in the heart and restoring blood flow. However, unlike a metallic stent, which cages the vessel, Absorb is more flexible and dissolves over time, leaving behind a treated vessel free of a permanent implant with the potential to flex, pulse and dilate in response to various demands on the heart, based on people's lifestyle and activities, such as exercise. At one year, the patient-oriented clinical endpoint of all death, all heart attacks and all revascularization was 7.3% for Absorb and 9.1% for XIENCE (p=0.47). The device-oriented clinical endpoint of target lesion failure (TLF) was 4.8% for Absorb and 3.0% for XIENCE (p=0.35) at one year. The individual components of these composite endpoints were also comparable between the two treatment groups. The rates of stent thrombosis (ST) observed for Absorb at one year were low at 0.6% for definite ST and 0.9% for definite/probable ST. The data also showed that during the course of one year, people treated with Absorb were less likely to experience angina once they left the hospital than those treated with XIENCE, at a rate of 16.4% versus 25.6% (p=0.01), respectively. Angina occurs when there isn't enough oxygen-rich blood flowing to the heart muscle. Angina has a significant impact on quality of life and healthcare costs. Overall, people who have angina following a heart stent procedure use more healthcare resources, including additional diagnostic and treatment tools to try to identify the source of angina, than those without angina. In addition, they typically have a lower quality of life because they are less likely to lead active lifestyles than those people without angina. Therefore, reducing the burden of angina could help people live healthier lives and reduce costs to the healthcare system. The primary endpoint of the ABSORB II trial is vessel motion at three years, at which time Absorb has fully dissolved. Without a permanent stent caging the vessel, the vessel has the potential to return to a more natural state. Clinical endpoints and quality of life measures will be assessed annually for up to three years. Imaging endpoints, or specialized pictures inside the blood vessel, will be assessed at three years.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ABT:US $43.38 USD +0.48

ABT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actavis plc $237.09 USD -1.67
Danaher Corp $78.73 USD +1.16
Medtronic Inc $65.98 USD -0.21
Teva Pharmaceutical Industries Ltd $52.37 USD +0.14
Thermo Fisher Scientific Inc $123.60 USD +0.99
View Industry Companies
 

Industry Analysis

ABT

Industry Average

Valuation ABT Industry Range
Price/Earnings 31.0x
Price/Sales 3.0x
Price/Book 2.7x
Price/Cash Flow 20.6x
TEV/Sales 2.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ABBOTT LABORATORIES, please visit www.abbott.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.